Tabla de Contenidos:
  • Half Title Page
  • Title Page
  • Copyright page
  • Contributors
  • Preface
  • Dedication
  • Table of Contents
  • Chapter 1: Epidemiology of Prostate Cancer: an Overview
  • Chapter 2: Epidemiology of Prostate Cancer in African Americans
  • Chapter 3: Epidemiology of Prostate Cancer in Africa
  • Chapter 4: Prostate Cancer among the Chinese: Pathologic, Epidem
  • Chapter 5: Epidemiology of Prostate Cancer in Jamaicans
  • Chapter 6: Epidemiology of Prostate Cancer in Hispanic Americans
  • Chapter 7: Assessment of Risk of Prostate Cancer: Algorithms for
  • Chapter 8: Molecular Factors in the Assessment of Prostate CancerChapter 9: Screening for Prostate Cancer: an Overview
  • Chapter 10: The Optimal Diagnostic Tool: Assessment of Diagnostic
  • Chapter 11: Screening for Prostate Cancer: the Case for Screening
  • Chapter 12: Screening for Prostate Cancer: the Argument for Cauti
  • Chapter 13: Natural History of Localized Adenocarcinoma of the Pr
  • Chapter 14: Prostate Physiology and Regulation
  • Chapter 15: Pathobiology of Prostate Diseases: an Update
  • Chapter 16: Models of Prostate Cancer
  • Chapter 17: Diagnosis of Prostate CancerChapter 18: Staging of Prostate Cancer
  • Chapter 19: Radical Prostatectomy: Patient Preparation
  • Chapter 20: Stage T1a Prostate Cancer: the Case for Treatment
  • Chapter 21: T1b-T2NxM0: the Case for Observation
  • Chapter 22: Radical Retropubic Prostatectomy for Clinical Stage T1b
  • Chapter 23: Radical Perineal Prostatectomy
  • Chapter 24: Continence-Enhancing Modifications for Radical Prostat
  • Chapter 25: T1-T2NxM0: the Case for External Radiotherapy
  • Chapter 26: Permanent Low-Dose-Rate Interstitial Brachytherapy
  • Chapter 27: T1b-T2NxM0: a Case for Hormonal Therapy?Chapter 28: Role of Cryosurgery in the Treatment of Prostate Cancer
  • Chapter 29: Should T1c Disease Be Treated Differently from T2 Dise
  • Chapter 30: T3-T4NxM0: the Case for Observation
  • Chapter 31: T3-T4NxM0: the Case for Radiotherapy
  • Chapter 32: Clinical-Pathologic T3NxM0 Prostate Cancer: the Case
  • Chapter 33: Node-Positive Prostate Cancer: the Case for Observatio
  • Chapter 34: TxN+M0: the Case for Radiotherapy
  • Chapter 35: TxN+M0 Disease: the Case for Early Hormonal Therapy
  • Chapter 36: TxNxM1: the Case for MonotherapyChapter 37: TxNxM1: the Case for Total Androgen Deprivation
  • Chapter 38: Is Early Hormonal Therapy Preferable?
  • Chapter 39: Staging Failures of Initial Therapy
  • Chapter 40: Management of Prostate-Specific Antigen Failure after
  • Chapter 41: Management of Local Failure following Treatment of Lo
  • Chapter 42: Secondary Hormonal Therapy
  • Chapter 43: Management of Hormone-Refractory Prostate Cancer:
  • Chapter 44: The Artificial Genitourinary Sphincter